Fresenius : publishes financial results for the second quarter and first half of 2022 in line with preliminary results

Contact

Markus Georgi

Senior Vice President Investor Relations & Sustainability
T: [phone]
[e-mail]

Download

• Text as PDF document(PDF, 282 KB)
• Q2/2022 Key Figures(XLSX, 332 KB)

All | None

Download

• Business development marked by significantly worsening headwinds at Fresenius Medical
• Care and increased macroeconomic challenges
• Fresenius Medical Care Business development impacted by unprecedented U.S. labor
• market situation and worsening macroeconomic environment
• Fresenius Kabi with solid organic sales growth despite tough prior-year-quarter
• Fresenius Helios with continued good admissions growth in Germany and Spain
• Fresenius Vamed still impacted by ongoing headwinds; service business supported by
• increasing elective treatment activity
• Cost and efficiency program evolving according to plan
• Starting date for Dr. Carla Kriwet as CEO of Fresenius Medical Care advanced to
• October 1, 2022

The full text of the Investor News will be available shortly. Please use the PDF document until then.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.